Case Study: Biogenesis Limited
- Deal size:
- Company Sales
- Deal completed:
- February 2005
Meridian Corporate Finance LLP (“Meridian") advised management on the sale of Poole based Biogenesis Ltd and USA based Biogenesis Inc to MorphoSys AG, a quoted company on Frankfurt Stock Exchange.
The £5.25m sale was concluded in a little over 12 weeks. The acquisition establishes MorphoSys as one of the top 5 European suppliers of antibodies to the sciences research community.
John Coward, the previous Managing Director of Biogenesis Ltd has become Chairman of the UK subsidiary. Commenting on the transaction John says, "The team at Meridian have helped us achieve the best possible deal in a relatively short space of time. The negotiations have been fast paced and fraught at times, but the quality of advice and personal attention has been excellent throughout the process."
Darren Thompson, Partner of Meridian said "The acquisition of Biogenesis Ltd and its sister company Biogenesis Inc is a great move for the German quoted company. We have significant experience in managing complex transactions of this nature and this demonstrates that international deals can be managed locally."